Read, understand and consent to the blog's DISCLAIMER here before proceeding to read the article
My partner site Medicoinvestor had this interesting update on Apaziquone -> Link
Time to recurrence is the key end point in the new phase 3 trial and pooled data from prior studies showed statistical significance of time to recurrence (p-value = 0.0076) on this end point. This is exactly the kind of sleuthing this blog intends to do. If you like this , I recommend you subscribe to our blogs for free to receive posts directly to your email.
Company's last PR on Apaziquone is here